ROLE OF THE INVESTIGATOR

Benjamin Kuo, MD, Dr.PH, CIP

Outline

- Definitions - Investigator
- Investigator responsibilities
  - Before the trial
  - During the trial
  - After the trial
- Conclusion

Investigator

person responsible for the conduct of the clinical trial at a trial site; the principal investigator is responsible leader of the clinical trial team

Sub-investigator

an individual member of the clinical trial team designated and supervised by the principal investigator to perform critical trial-related procedures and/or make trial-related decisions

The Good Investigator

- Is interested in the scientific aspects of the study and ensures that the study is responsive to the needs of public health within the country or population in which it will be conducted
- Has sufficient time free from other obligations to prepare and conduct the trial including time to inform and supervise study staff
- Puts the welfare and interest of the patient as foremost priority
- Ensures the confidentiality of the product, the protocol and the trial procedures

試驗主持人

- 符合主管機關規定之資格及能力(GCP第卅條)
- 熟悉...試驗計畫書...。 (GCP第卅一條)
- 明瞭並遵守本準則及相關法規之要求。(GCP第卅二條)
- 接受試驗委託者之監測與稽核，並接受主管機關或其指定機構之查核。 (GCP第卅三條)
- 確保所有試驗相關人員對試驗計畫書及研究藥品充分了解，以及其於臨床試驗中之責任與工作。(GCP第卅八條)

Adequate Resources

Investigators' Responsibility

- Patient
- Time
- Staff
- Space
- Facilities

試驗主持人

- ✓ Adequate resources, including facilities, patient pool, qualified staff & time allocation
- ✓ Medical care for trial subjects, including management of adverse events
- ✓ Communication with IRB/EC
- ✓ Informed consent of trial subjects
- ✓ Follow protocol
- ✓ Maintain control of study drugs

試驗主持人

- ✓ Keep accurate records - originals
- ✓ Keep trial subjects, IRB/EC and sponsor informed of new developments as appropriate, including reporting and management of AEs/SAEs within the agreed timescales
- ✓ Send progress reports to IRB/EC as required (but at least once a year)
- ✓ Retain study documents as required
- ✓ Permit audit/inspection of site and records by the Sponsor/Regulatory Authorities (e.g., DOH)

Responsibilities before the trial

Areas of Responsibility

1. Qualifications and agreements
2. Resources
    a. Staff
    b. Recruit appropriate participants and facilities
    c. Archives
3. Communication with IRB/ EC
4. Submission of necessary documents to EC and clinical monitor

1. Qualifications and agreements

- Qualified by education, training and experience (and provide evidence)
- Familiar with the investigational product (as described in the protocol, investigator's brochure, product information)
  - Pre-clinical toxicology
  - Pharmacology
  - Pharmacokinetics
  - Up-to-date clinical data

1. Qualifications and agreements

- Aware of, and complies with GCP and regulatory requirements
- Should permit monitoring, auditing and inspection

2. Resources - Staff

- **Have adequate number of qualified staff**
  - **Authorized signatory form**
  - **Curriculum vitae**
- **Ensure that all persons assisting with the trial are adequately informed about the protocol, investigational product, and their trial-related duties and functions**

2. Resources – Recruitment and Facilities

- **Able to recruit the required number of suitable subjects within the agreed recruitment period**
- **Ensure that the physical location and facilities are sufficient to allow the study to be undertaken efficiently**
  - **Confidentiality and safety conditions for trial subjects**
  - **Adequate equipment/facilities for subject follow-up, examination and care**
  - **Adequate facilities for laboratory assay**
  - **Adequate facilities for product storage**

2. Resources – Considerations for document archiving

- **IRB/EC should retain all relevant records (members, submitted documents, minutes of meetings, correspondence) for at least 3 years after completion of a trial**
- **ICH GCP – trial documents are retained until at least 2 years after the last approval of a marketing application and until there are no pending marketing applications or until at least 2 years since discontinuation of a clinical development of the product**

2. Resources – Considerations for document archiving

- Patient ID list retained for minimum of 15 yrs after completion or suspension of a trial (or longer)
- Patient files and source documents > 10 yrs
- Sponsor recommendation
- Safe, secure, and maintains patient confidentiality

3. Communicate with IRB/EC

- Obtain written approval for
  - the trial protocol
  - written patient information sheet
  - informed consent form
  - subject recruitment procedures
- Assurance that the trial shall be monitored by the IRB/EC
- Submit to the sponsor composition of the EC

4. Documents (and information) – Submission to IRB/EC

- Investigator's brochure and up-to-date safety information
- Trial protocol (final version and amendments)
- Consent forms and patient information sheet
- Subject recruitment procedures, incentives
- Information on payment and compensation to subjects
- CVs of staff, institutional affiliations
- Potential conflicts of interest
- Other documents requested by the IRB/EC

4. Documents for clinical monitor inspection

- Approved protocol, signed and dated
- Approved informed consent form and other subject information
- CVs of investigators and other members
- Authorized signatory form
- Product exportation/importation authorization
- Laboratory certification, list of normal ranges → signed by PI
- Technical services agreement
- Signed agreement that the product will not be used before the trial initiation visit and authorization from TDR

Responsibilities during the trial

Areas of responsibility during the trial

1. Screening and recruitment of study participants
2. Informed consent from trial participants
3. Compliance with the EC-approved protocol
4. Provision of medical care to trial participants
5. Randomization procedures and unblinding
6. Safety reporting
7. Completion and validation of the case report form
8. Product storage and accountability
9. Premature termination or suspension of a trial
10. Progress and final reports

1. Screening and recruitment of study participants

- Dedicates time to the recruitment of suitable trial subjects
- Resolves all questions from staff re: interpretation of inclusion and exclusion criteria
- Ensures unbiased selection of an adequate number of suitable subjects

2. Informed consent from trial participants

- Prospective subject or representative had sufficient opportunity to consider whether or not to participate
- Consent was sought under circumstances that minimized the possibility of coercion or undue influence
- Information that was given to the subject or representative was in a language understandable to them

Informed consent prior to participation

- Trial procedures and point at which consent is taken
- Names in the screening and enrolment log and in the informed consent (IC) form
- Trial timelines and dates of signatures in the IC form and other documents
- Participant’s age and assent to participate

3. Protocol compliance

- **Once the study has started, the investigator must adhere to the protocol and ensure that it is strictly followed**
  - **Document approved by the IRB/EC**
  - **Contract signed during trial initiation: AGREEMENT BETWEEN WHO/TDR AND THE INVESTIGATOR ON THE CONDUCT OF THE WHO/TDR PROTOCOL**
- **Protocol violation**

3. Protocol compliance - amendments

- **Protocol deviation (or changes) – implemented after agreement with sponsor and amendments approved by EC**
- **Exceptions (but still need approval)**
  - **– Necessary to eliminate hazard/s to participant**
  - **– Change in logistics and administrative aspects**

4. Providing medical care for subjects

- A qualified physician (investigator or sub-investigator) must be responsible for all trial-related medical decisions
  - Adequate care for any adverse event
  - Inform primary physician about participant in the trial (if applicable and participant agrees)
  - Ascertain participant's withdrawal from the trial while respecting participant's rights

5. Randomization and unblinding

- Randomization procedure is strictly followed
- Code is broken following the protocol and mainly for medical reasons
- Premature unblinding is reported immediately to the clinical monitor and documented in the investigator’s file; reason provided
- All unbroken codes are returned to the clinical monitor to prove that the study was blinded

6. Study and reports

- **Safety reports**
  - **AEs and SAEs reporting should follow sponsor SOPs for the trial**
  - **Applicable regulatory requirements**
  - **IRB/ERB SOPs**
- **Continuing reports/progress reports**
- **Should maintain participant privacy and confidentiality**

不良事件 vs 不良反應

- 不良事件（Adverse event）：
  - 受試者參加試驗後所發生之任何不良情況。此項不良情況與試驗藥品間不以具有因果關係為必要。
- 藥品不良反應（Adverse drug reaction）：
  - 使用藥品後所發生之有害且未預期之反應。此項反應與試驗藥品間應具有合理之因果關係。

嚴重不良事件

Serious adverse event（SAE）

- Any untoward medical occurrence that at any dose:
  - 死亡 results in death
  - 危及生命 life-threatening
  - 住院或延長住院 requires inpatient hospitalization or prolongation of existing hospitalization
  - 永久失能 results in persistent or significant disability/incapacity
  - 先天畸形或畸胎 congenital anomaly/birth defect
  - 其他重大傷害 results in another medically important condition

7. Case report form

- **Accurate, legible and complete data are entered in the CRFs and in all required report forms/logs**
- **Allows only authorized staff to enter data into the CRF and other required report forms.**
- **CRFs are completed during subject participation in the trial.**

Source documents

- Keeps all original documents or certified copies containing data related to clinical trial activities (source data), necessary for reconstruction of the trial
- Ensures that data in the CRF should be consistent with the source documents
- Allows direct access for monitoring, auditing, IRB/EC review, and regulatory inspection

What is a source document?

Original documents, data, and records:

- Hospital records
- Clinical and office charts
- Laboratory notes,
- memoranda,
- Subjects diaries or evaluation checklists
- Pharmacy dispensing records
- Recorded data from automated instruments
- Copies or transcriptions certified after verification as being accurate and complete
- Photograph negatives (e.g. x-ray films)
- Microfilm or magnetic media
- Subject files
- Records kept at
  - Pharmacy
  - Laboratory
  - Other departments involved in the trial

When filling in the CRF . . . .

- **Uses ballpen**
- **Uses capital letters**
- **Completes all items by entering a number or text in the provided space**

|C|O|M|P|L|E|T|E| |A|L|L| | I|T|E|M|S|

1,000 | ?| ?| ?| | ?| ?| ?

When correcting the CRF . . .

29/02/05

01/0**3**/05

~~29/02/05~~
01/03/05 XY

- **Original entry not obscured**
  - **Does not erase**
  - **Does not overwrite**
  - **Does not use correcting fluid**
- **Writes correct entry beside, above or under wrong entry**
- **Dates correction**
- **Initials correction**
- **Explains correction (if needed)**
- **Only authorized staff can make corrections; not clinical monitor nor sponsor**

8. Product management

- Ensures that the product is properly received, stored and handled
- May assign an appropriate person for storage and accountability at the trial site (but still under supervision of the investigator)
- Follow storage conditions specified by sponsor, and according to the protocol and regulatory requirements (e.g. temperature)
- Maintain temperature log of storage conditions

Product accountability

- Files records of delivery, inventory and return
  - Dates (manufacturing, expiration)
  - Quantities, batch/serial numbers
  - Unique code number assigned to product and trial subjects
- Keeps trial accountability log up-to-date
- Maintains a treatment log that documents that participants were given dose specified in protocol

Treatment compliance

- Uses product only in accordance with the approved protocol
- Explains correct use of the product to each participant and makes sure that instructions are followed

9. Premature termination or suspension of the trial

- By the investigator
  - →Institution
  - →IRB/ERB
  - →Sponsor
- By the sponsor → institution
- IRB/ERB terminates or suspends its approval
  - →Institution
  - →Sponsor
- Promptly inform trial subjects and assure appropriate treatment and follow-up
- Inform regulatory authority
- Written explanation

10. Progress and final reports

- **According to institutional, IRB policies and protocol/sponsor requirements**

Responsibilities at the end of the trial

1. Record retention

- Subject screening and enrolment log
- Identification of enrolled participants
- Signed informed consent and related documents
- IRB communications, approvals
- Amendments
- Continuing review
- Product management and accountability

2. Trial materials and equipment

- Return unused product, trial equipment, unused trial documents to the sponsor
- Sponsor instructions with regard to unused products
  - Destruction
  - Compassionate use of unused products

Other obligations

- Final reports - provide final reports to IRB/EC, regulatory authority and sponsor
- Publication policies
- Audit and inspection procedures
- Planned follow-up activities related to development of the product

Conclusion

Adherence to investigator responsibilities assures

- **credibility of the data,**
- **well-being, safety and protection of the rights of research subjects engaged in clinical trials**

Adherence to good clinical practices


association
clinical
research
professional
ACRP
ASSOCIATION OF CLINICAL RESEARCH PROFESSIONALS
About ACRP | Media | SiteMap | Contact ACRP
JOIN ACRP!
APPI
Public Policy
Education
Certification
Conferences
Career Center
Membership
SEARCH
Think global.
The Association Board of Trustees has made global expansion of membership its second-highest priority in our new strategic plan. Through education and certification, ACRP is making strides to harmonize the clinical research experience for human subjects around the world. Read here about our recent efforts.
Email:
Password:
Login
[Forgot login info?]
Chapters & Forums
US Chapters
Global Chapters
Forums
Get Involved
Find a Member
Shop for Products
Network
Get Certified
Upcoming Events
01/30/08
Recruitment Beyond Your Own Practice
Global Conference
ACRP 2008 in Boston
Advance registration has begun for the ACRP 2008 Global Conference & Exhibition. ACRP and APPI members who register from
Education
Prepare for Your Certification Exam
Sign up today for Certification Exam Review courses in preparation for March 8 Certification
Certification
Get Certified
Applications for March 8 Certification Exams are due Feb. 4 with a $150 late fee. As the leading provider of certification programs for
Online Learning
Online Courses Available Now
If you are comfortable with self-directed learning and want to save on travel and lodging expenses, then
網際網路

Academy of Pharmaceutical Physicians and Investigators (APPI)
(an Affiliate of ACRP)
March 2008 Certification Application Form

Taiwan ICH CPI Exam

While you cannot submit this form electronically,
you can complete it online, print it, and send it to FMPAT.

Application Deadline: 21 January 2008
Exam Date: 8 March 2008

Important Application Information

- Make sure you are filling out the correct application form.
- Note: only ***physician investigators*** will be accepted to sit for this CPI examination.
- Accurately complete the Statement of Experience section.
- Sign and date the application form in the Agreement of Authorization of Confidentiality and Payment sections.
- Include a copy of your C.V. that is signed and dated.
- Submit copies of both sides of signed investigator agreements with the application. Failure to provide this detailed information will result in ineligibility.

推

您尚未登入
登入 或 加入會員

新活動訊息

NEW! 2008年ACRP講師培訓認證課程
2008/1/13 - 2008/1/13

2007年9月ACRP臨床試驗人員認證考試
2007/9/8

活動種類

- 其他課程研習會
- ACRP臨床人員驗證考試
- 2007年臨床試驗訓練課程
- 2007年全民外交研習營活動
- 2007全球衛生論壇系列講座(一)
- 新聞稿發佈區

ACRP臨床人員驗證考試

活動清單 友善列印

2008年3月ACRP臨床試驗人員驗證考試

活動日期 : 2008年3月8日～2008年3月8日
時間 : 2008年3月8日 13:30~16:30
地點 : 立德台大尊賢會館 B01會議室 地址:台北市羅斯福路四段83號（台北捷運公館站銘傳國小出口）
聯絡方式 : 02-23212362 ext.23 陳小姐或 ext.20 沈小姐

＊考試簡介下載

ACRP 考試簡介

2008年 ACRP臨床試驗人員認證考試

報名日期：即日起~2008年1月21日（礙於美國ACRP規定，必須將文件在１月２１日送

主辦單位：Association of Clinical Research Professionals (ACRP)

承辦單位：財團法人台灣醫界聯盟基金會

100 台北市仁愛路一段四號三樓

電話：02-2321-2362 ext.23或20 / 傳真：02-2...

Foundation of Medical Professionals Alliance in Taiwan (FMPAT)

3F, No. 4, Sec. 1, Ren-Ai Rd.Taipei, Taiwan

TEL：886-2-2321-2362 ext. 23 or 20 / FAX：886-2-2...

(最後修改日期：2008/01/16 11:22 AM)

下一則

報名費用：

Test	Member	Non-member (apply for exam and joint ACRP)	Nonmember (apply for exam only)
CRA	399 USD	519 USD*	549 USD
CRC	369 USD	489 USD*	519 USD
CPI	469 USD	589 USD**	619 USD

日期	類別	報名人數	不合格	合格	通過人數	通過率（%）
20050917	CRA	18	2	16	10	63
	CRC	10	1	9	5	56
	CPI	28	10	18	9	50
20060311	CRA	10	2	8	2	25
	CRC	6	1	5	1	20
	CPI	12	3	9	4	36
20060909	CRA	10	0	10	5	50
	CRC	8	2	6	3	50
	CPI	7	1	6	2	33

ACRP臨床試驗人員認證考試 複習課程

課程內容：

Certified Physician Investigator (CPI)認證複習課程培訓班 Clinical Research Associate (CRA)認證複習課程培訓班 Clinical Research Coordinator (CRC)認證複習課程培訓班 ACRP複習課程講員培訓班 以上各班培訓時間計1天，並請隨時參閱www.mpat.org.tw公告之開班日期即時訊息。

課程對象：

有志於參與ACRP臨床試驗人員認證考試之臨床試驗人員 （已通過ACRP認證考試者方可參加ACRP複習課程講員培訓！）

報名方式：網路報名 www.mpat.org.tw

主辦單位：

經濟部工業局
財團法人台灣醫界聯盟基金會
工業技術研究院
Association of Clinical Research Professionals

報名時間：即日起至2006年8月22日
開課時間：2006年8月26-29日 講員：Dr. Sinisa Radulovic, MD, CPI（由美國ACRP邀請國際知名講員）
地點：台北市青少年育樂中心 6F數位教室B（台北市仁愛路一段17號）

費用：

ACRP會員 13,100TWD/班次
非ACRP會員 17,000TWD/班次


財團法人台灣醫界聯盟基金會 - Microsoft Internet Explorer
檔案(F) 編輯(E) 檢視(V) 我的最愛(A) 工具(T) 說明(H)
上一頁 搜尋 我的最愛
網址(D) http://www.mpat.org.tw/
移至 連結
Google 醫界聯盟基金會 開始 書籤 16 已攔截 拼字檢查 傳送到 醫界聯盟基金會 設定
登入 或 加入會員
新活動訊息
2008年3月ACRP臨床試驗人員驗證考試 2008/3/8 - 2008/3/8
NEW! 2008年ACRP臨床試驗人員驗證考試複習課程 2008/1/14 - 2008/1/15
活動種類
其他課程研習會
ACRP臨床人員驗證考試
2007年臨床試驗訓練課程
2007年全民外交研習營活動
2007全球衛生論壇系列講座(一)
新聞稿發佈區
活動清單
友善列印
2008年ACRP講師培訓認證課程
活動日期 : 2008年1月13日～2008年1月13日
時間 : 上午9點至下午5點
地點 : 立德台大尊賢會館 地址：台北市羅斯福路四段83號 (捷運公館站銘傳國小出口)
聯絡方式 : 02-2321-2362 分機23陳小姐/分機20沈小姐
ACRP首次在台針對已通過考試者舉辦講師培訓認證課程，由ACRP專門講師授課，敬請把握機會！
場地人數有限，請盡速報名以免向隅！
◎報名時間：即日起～2008.01.10
◎招生對象：已通過ACRP考試認證者
◎培訓日期：2008年1月13日
◎培訓時間：上午9點~下午5點
◎培訓費用：非ACRP會員新台幣17000元
ACRP會員新台幣13100元
◎課程地點：立德台大尊賢會館 B01會議室
台北市羅斯福路四段83號（台北捷運公館站銘傳國小出口）
完成
網際網路
開始
C:\Documents and Sett...
ROLE OF THE INVE...
財團法人台灣醫界...
上午 10:45

「提升醫療機構人體試驗委員會倫理審查品質訓練計畫」

郭英調

台北榮民總醫院 感染科醫師、教學研究部

國立陽明大學 臨床醫學研究所副教授

聯合人體試驗委員會 執行秘書

全部委員考試

	考試	不過	通過
8月27日	43	1	42
8月29日	114	5	109
9月3日	132	8	124
9月12日	50	2	48
10月1日	6	0	6 (補考)
10月10日	130	24	106
10月15日	149	15	134
11月5日	12	0	12 (補考)
總計	636	55	581

全部PI考試

	考試	不過	通過
8月18日	102	5	97
9月12日	341	32	309
9月17日	161	8	153
10月13日	277	56	221
10月1日	279	26	253
10月24日	213	15	198
11月5日	118	1	117
總計	1491	143	1348


เจริญศรี 3